Mid-cap drugmakers face limited impact from Trump drug pricing deals, analysts say
BUZZ-Mid-cap drugmakers face limited impact from Trump drug pricing deals, analysts say ** Impact of the Trump administration's new round of drug-pricing agreements with mid-sized biotech companies will be muted, RBC Capital Markets says
** On Monday, the Trump administration signed deals with companies including Astellas 4503.T, BeOne Medicines 688235.SS and BridgeBio BBIO.O
** These companies have offered drugs to state Medicaid programs at most-favored-nation prices, that would require U.S. drug prices to be pegged to the lowest price paid by comparable high-income countries
** Medicaid already receives some of the steepest drug discounts, and exposure to the program is limited for most of the mid-cap companies we cover, RBC Capital Markets analysts said
** "We do not see our covered names sustaining any meaningful commercial impact and we think the perception of a removed overhang could, if anything, bring incremental upside" RBC analysts
** For BBIO, analysts said the deal has limited impact commercially as Medicaid represents less than 2% of Attruby net sales
** Up to last close, Tokyo-listed shares of Astellas were up 15.4%, U.S.-listed shares of BeOne up 18.4%, BBIO up 0.13% YTD
(Reporting by Sneha S K)
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels